Psychedelic 5-MeO-DMT infused in healthy brains: first safety data coming
NCT ID NCT07444788
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing how safe and tolerable intravenous 5-MeO-DMT is in 40 healthy adults aged 25-65. Participants receive either a low dose of the psychedelic or a placebo, and researchers monitor their subjective experiences, vital signs, and side effects. The goal is to gather basic safety and drug-effect data, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 5-MeO-DMT (a psychedelic compound)
- What this could lead to
- If successful, this study could help establish safe dosing guidelines for 5-MeO-DMT in future therapeutic research.
- What could go wrong
- This is an early Phase 1 safety study in healthy volunteers, not a treatment trial. The drug may cause unpleasant psychological or physical effects, and results may not translate to patient populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for 5-METHOXY-DIMETHYLTRYPTAMINE (5-MEO-DMT) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Basel
RECRUITINGBasel, Canton of Basel-City, 4056, Switzerland